Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help. Objective: To see if the Elidah device can reduce urinary incontinence after prostate treatment. Eligibility: Men aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer. Design: Participants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests. The Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis. Participants will be given an Elidah device and taught how to use it at home. They will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks. Participants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads. Participants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used. Participants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment. Participants will complete 15-minute questionnaires.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyzna w wieku 18 lat lub więcej
- •Co najmniej 6 miesięcy niekontrolowanych wycieków moczu po leczeniu raka prostaty
- •Przeciętne nasilenie problemów (używanie 1-4 podpasek dziennie)
- •Wycieki podczas wysiłku lub naglące potrzeby oddawania moczu
- •Umiejętność czytania i pisania w języku angielskim
- •Zdolność do podpisania zgody na udział w badaniu
✗ Disqualifies
- •Zaplanowana zmiana leczenia raka prostaty podczas badania
- •Historia zatrzymania moczu lub opróżniania się pęcherza
- •Aktywne lub częste infekcje dróg moczowych (4 lub więcej w ciągu roku)
- •Metalowe implanty w brzuchu lub miednicy
- •Implant kardiologiczny lub zaburzenia rytmu serca
- •Historia epilepsji
- •Zaburzenia neurologiczne wpływające na kontrolę moczu
- •Zmiana leków na wycieki moczu w ciągu ostatnich 2 tygodni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 120 Years
- Last updated (source)
- July 24, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Debbie-Ann N Nathan, R.N.
Deborah E Citrin, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.